- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Hyloris Developmentsen Sa (HYL)
Hyloris Developmentsen Sa stock price live, this page displays EBR HYL stock exchange data. View the HYL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Hyloris Developmentsen Sa real time stock price chart below.
What Is the Hyloris Developmentsen Sa Stock Price Today?
The Hyloris Developmentsen Sa stock price today is 4.71.
What Is the Stock Symbol for Hyloris Developmentsen Sa?
The stock symbol for Hyloris Developmentsen Sa is "HYL."
What Stock Exchange Does Hyloris Developmentsen Sa Trade On?
Hyloris Developmentsen Sa is listed and trades on the Brussels stock exchange.
Is Hyloris Developmentsen Sa a Good Stock to Buy?
Determining whether Hyloris Developmentsen Sa—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HYL quote. (ISIN: BE0974363955)
What Is the Hyloris Developmentsen Sa Stock Price Today?
The Hyloris Developmentsen Sa stock price today is 4.71.
What Is the Stock Symbol for Hyloris Developmentsen Sa?
The stock symbol for Hyloris Developmentsen Sa is "HYL."
What Stock Exchange Does Hyloris Developmentsen Sa Trade On?
Hyloris Developmentsen Sa is listed and trades on the Brussels stock exchange.
Is Hyloris Developmentsen Sa a Good Stock to Buy?
Determining whether Hyloris Developmentsen Sa—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HYL quote. (ISIN: BE0974363955)
Brussels
Currency in EUR
4.71
-0.04(-0.84%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.61
4.79
52 wk Range
4.51
8.40
HYL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.614.79
52 wk Range
4.518.40
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HYL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
13.57
Upside
+188.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 13.57
(+188.04% Upside)
Earnings
Latest Release
Mar 26, 2026
EPS / Forecast
-0.10 / --
Revenue / Forecast
5.49M / --
Compare HYL to Peers and Sector
Metrics to compare | HYL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHYLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.2x | −2.2x | −0.5x | |
PEG Ratio | - | 0.15 | 0.00 | |
Price/Book | 5.1x | 1.0x | 2.6x | |
Price / LTM Sales | 16.9x | 6.8x | 3.0x | |
Upside (Analyst Target) | 122.9% | 81.0% | 58.6% | |
Fair Value Upside | Unlock | −4.1% | 10.2% | Unlock |
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis. In addition, the company is involved in the development of Alenura for painful bladder syndrome; Phosphate oral liquid for phosphate supplementation; and HY-095 PPI for the treatment of gastric ulcers in horses. Further, it develops Aspirin IV for acute coronary syndrome indication; Milrinone for late-stage HF with LVAD; Dofetilide IV for atrial fibrillation indication; HY-074 for acute coronary syndrome indication; Metolazone IV for congestive heart failure indication; and HY-75 for coronary heart disease indication. The company has collaboration agreements with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Ownership
Ownership Overview
People Also Watch
FAQ
What Is the Hyloris (HYL) Stock Price Today?
The Hyloris stock price today is 4.71 EUR.
What Stock Exchange Does Hyloris Trade On?
Hyloris is listed and trades on the Brussels Stock Exchange.
What Is the Stock Symbol for Hyloris?
The stock symbol for Hyloris is "HYL."
What Is the Hyloris Market Cap?
As of today, Hyloris market cap is 131.88M EUR.
What Is Hyloris's Earnings Per Share (TTM)?
The Hyloris EPS (TTM) is -0.23.
From a Technical Analysis Perspective, Is HYL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Hyloris Stock Split?
Hyloris has split 0 times.
How Many Employees Does Hyloris Have?
Hyloris has 55 employees.
What is the current trading status of Hyloris (HYL)?
As of Jun 15, 2026, Hyloris (HYL) is trading at a price of 4.71 EUR, with a previous close of 4.75 EUR. The stock has fluctuated within a day range of 4.61 EUR to 4.79 EUR, while its 52-week range spans from 4.51 EUR to 8.40 EUR.
What Is Hyloris (HYL) Price Target According to Analysts?
The average 12-month price target for Hyloris is 13.57 EUR, with a high estimate of 20.4 EUR and a low estimate of 6 EUR. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +188.04% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.